KEY FINDINGS
In 2017, the Europe DNA sequencing market captured a share of $2224 million in the global market. By the end of the forecast period of 20182026, the market is expected to rise with 17.50% CAGR and contribute a net revenue of $9497 million.
MARKET INSIGHTS
Europe enjoys a significant funding and infrastructure for cancer genomics, which helps to drive the DNA sequencing market adoption in this region. Largescale government funding, faster processing techniques and huge pharmaceutical industry investment are driving the U.K market. The country is expected to account for the highest revenue share by the end of the forecast period for the European region. Other significant markets in this region include Germany, Spain, France, Netherlands, Switzerland, and Austria. Hartwig Medical Foundation is the first national DNA data 'sequencing' centre in Netherland which caters to personalized cancer care. Switzerland's first highthroughput DNA sequencing platform, which could well become one of Europe's largest, has opened its doors on Campus Biotech in Geneva. It is increasingly focused on promoting personalized health care and precision medicine across Switzerland.
COMPETITIVE INSIGHTS
Some of the eminent companies in this region include Illumina, Roche Diagnostics, Thermo Fisher Scientifi Inc, Genomics Inc, Agilent Technologies Inc, Adaptive Biotechnologies Inc, Cell Microsystems Inc, Ubiquity Wafergen BioSystems Inc, Appistry Inc and Asuragen Inc.
Original Article: EUROPE DNA SEQUENCING MARKET FORECAST 20182026 [Report Updated: 15012018] Prices from USD $1250
NEXT ARTICLE